An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata:  A case report and a review of the literature

Alopecia areata is a common autoimmune disease, with a negative impact in health ‐related quality of life, especially when affecting children and adolescents. Current medical therapies, mainly for severe disease, are not effective (Semin Cut Med Surg, 2015; 34:72). There are no FDA (Food and Drug Administration) ‐ or ANVISA (Agência Nacional de Vigilância Sanitária)‐approved therapy for children with alopecia areata. JAK inhibitors are emerging as a promising therapy. AbstractAlopecia areata is a common autoimmune disease, with a negative impact in health ‐related quality of life, especially when affecting children and adolescents. Current medical therapies, mainly for severe disease, are not effective. There are no FDA (Food and Drug Administration)‐ or ANVISA (Agência Nacional de Vigilância Sanitária)‐approved therapy for children with alo pecia areata. JAK inhibitors are emerging as a promising therapy.

Source: Clinical Case Reports - November 20, 2019 Category: General Medicine Authors: Rachel Berbert Ferreira, Sineida Berbert Ferreira, Morton Aaron Scheinberg Tags: CASE REPORT Source Type: research